SVSB interacted closely with JK during the data collection phase and later towards the end of analysis, for analytic insights and validation of interpretations of the data in the manuscript.
There are many techniques to achieve the ends; for instance, analysis methods (cf. [3 6, 14, 16]), combinatorics method (cf. [17]), and q-operator method (cf. [7, 9 11, 19, 24]) and so on.
Patients who discontinued the study early because of lack or loss of response or for whom insufficient data were available were treated as not achieving the end points for analysis of the ITT population.
One hundred and twenty eight patients per arm, i.e. 16 groups of approximately 8 patients in each arm will give 94% power for the end of treatment analysis.
Most patients evaluated reached target HR at a dobutamine level of 30 μg/kg/min, which was then taken for all subjects to be the end time-point for analysis.
In another series of experiments, two groups of three animals each were xenografted with NCI-H460 as above, after which, starting from day 10 post xenograft, animals were treated daily with either vehicle or GS-168AT2 for 5 days, and tumour blocks were harvested at the end of treatment for analysis.
While public and scientific commentators, including EFSA [9], obviously assume that all animals tested per group and sex are in the end also used for analysis of e.g. biochemical parameters, the applicable OECD guidelines and several of the screened publications apply a different approach.
Samples of 100 mL were removed at the end of fermentation for analysis of aroma compounds.
After 2004, the prescription pattern of erythropoietins changed because of available data from abstracts of randomised controlled trials in chronic kidney disease and dialysis patients and therefore, despite availability of data on survival status and comorbidities up to 2008, we used the time range only up to the end of 2004 for analysis.
